Metofol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metofol

Quick Facts

Property Description
Active Ingredient Folic Acid (Pteroylglutamic acid)
Form Primarily Tablet or Capsule (Oral solid forms)
Pharmacological Class Water-soluble Vitamin (B-complex), Hematopoietic agent
General Purpose Supplementation to support fundamental cellular processes
Origin Synthetic

What Type of Medicine is Metofol, and What is its Composition?

Metofol is classified as a medicinal preparation whose sole active ingredient is Folic Acid, otherwise known as Vitamin B9. The substance, chemically identified as Pteroylglutamic acid, belongs to the water-soluble vitamin class and functions as a hematopoietic agent due to its role in blood formation. Folic Acid is vital for the synthesis and repair of DNA and RNA, making it an essential nutrient. The substance is recognized for its role in the growth and renewal of cells throughout the body.

Metofol is typically manufactured as a synthetic compound, which ensures high stability and purity compared to naturally derived folate. As a single-ingredient product, it combines the active molecule with necessary inactive excipients (such as fillers) to create stable oral solid forms like Tablets or Capsules for consumption via the oral route.


Metofol's Core Physiological Purpose

The primary general purpose of Metofol is to provide supplementation to ensure the body's metabolic demands for this compound are met. Folic Acid is essential for the continuous and healthy process of Cell Division and growth. The product is commonly positioned as an Over-the-Counter (OTC) supplement designed for the general population needing nutritional support.

Folic Acid is crucial for the healthy maturation of red blood cells (erythropoiesis) within the bone marrow, an essential function. This type of supplementation is particularly relevant during periods of rapid cell turnover. By supporting these foundational biological activities, Metofol helps maintain healthy blood composition and the body's general cellular health.

Regulatory References

  1. Folic Acid Tablets, USP Product Monograph

What side effects are possible with Metofol?

Possible side effects and safety information

Metofol, whose active ingredient is Folic Acid, possesses a safety profile that is generally favorable at standard therapeutic doses. According to regulatory documentation, adverse reactions are typically infrequent or rare and usually non-severe.

Documented Adverse Reactions

The officially documented adverse reactions for Folic Acid are generally categorized into effects on several system-organ classes:

  • Immune System and Skin Disorders: These include symptoms related to hypersensitivity, such as rash, pruritus (itching), and erythema (redness of the skin).
  • Gastrointestinal Disorders: These effects may include anorexia (loss of appetite), nausea, flatulence, and abdominal distention.
  • Nervous and General Disorders: Other documented effects include irritability, sleep disturbances, and general malaise.

While serious allergic reactions (anaphylaxis) are included in the overall safety documentation, they are considered extremely rare.

Key Safety Restriction

The most critical regulatory safety limitation documented for Folic Acid relates to its use in certain blood disorders. Metofol must not be used alone to manage megaloblastic anemia until a deficiency in Vitamin B12 has been officially ruled out. Regulatory authorities mandate this restriction because Folic Acid can correct the appearance of the blood cells (hematological signs) associated with Vitamin B12 deficiency but does not prevent the progression of severe, often irreversible neurological damage (such as subacute combined degeneration of the spinal cord). This potential to mask a serious underlying condition defines the drug’s primary safety constraint.

Overdose and Emergency Response

Metofol Overdose and when to seek help

Metofol is a drug primarily used to treat megaloblastic anemia caused by folic acid deficiency. While folic acid itself is a water-soluble B vitamin, and typically does not cause acute toxicity in high doses, taking a massive Metofol overdose is still dangerous and warrants immediate medical attention, especially if Metofol is part of a combination product containing other active ingredients. Large excess doses, particularly of certain multivitamin formulations containing Metofol, can lead to adverse effects.

Signs of a severe overdose can vary based on the specific formulation but may include gastrointestinal issues like nausea, vomiting, or diarrhea, and in rare, massive cases, central nervous system symptoms like confusion or seizures.


When to Seek Immediate Medical Help

A Metofol overdose is a medical emergency. Contact your local emergency services immediately if you, or someone else, has taken more than the prescribed dose and shows any of the following serious symptoms:

Symptom Category Examples of Serious Symptoms
Cardiovascular/Respiratory Difficulty breathing, chest pain, irregular or rapid heartbeat.
Neurological Confusion, severe drowsiness, seizures, or loss of consciousness.
Gastrointestinal Severe or bloody vomiting or diarrhea.

Be prepared to provide the name of the medication, the amount taken, and the time it was swallowed. Do not wait for symptoms to worsen; immediate medical evaluation is essential.

Therapeutic Uses of Metofol

What Metofol Treats: Main Uses and Benefits

Metofol is commonly used across domains where additional symptomatic support is needed, addressing symptoms related to heightened physiological activity. It is relevant in situations involving certain distressing symptoms, such as high blood pressure, chest pain (angina pectoris), and certain irregular heart rhythms. The core application is to manage key symptomatic and systemic discomfort.


Supportive Symptom Management

Metofol is relevant for managing symptom clusters that interfere with daily comfort and may become disruptive, including symptoms related to physical discomfort. It is often used during phases when symptoms become more noticeable, applied in clinical settings that involve acute or unstable symptom patterns. It provides support that helps ease the overall symptom burden.

Assisting Functional Stability

This medication is commonly used across condition categories involving episodic or fluctuating manifestations. In these scenarios, it may assist with maintaining functional stability when symptoms lead to temporary functional strain or discomfort. It may help patients cope more steadily with symptom fluctuations, contributing to improved comfort during symptomatic periods.


Quick Facts: Therapeutic Use

  • Condition Categories: Used in conditions involving episodic or fluctuating manifestations.
  • Symptom Domains: Addresses symptoms related to physical discomfort and heightened physiological activity.
  • Benefit: Contributes to improved comfort during periods of heightened symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Metofol?

The eligibility to use Metofol (Metoprolol) is strictly defined by regulatory authorities based on a patient's existing health status and age. This information comes directly from official prescribing documents, such as FDA and EMA labels.

Contraindicated Populations

Metofol is formally contraindicated and must not be used by patients presenting with specific severe, uncontrolled cardiac conditions. These include Cardiogenic Shock, Decompensated Heart Failure, Severe Bradycardia (very slow heart rate), or Second- or Third-Degree Atrioventricular (AV) Block unless a functioning pacemaker is present. Use is also prohibited for individuals with known hypersensitivity to the drug.

Age and Health Restrictions

Metofol is generally approved for adult use. In the pediatric population, use for hypertension is only established for children ge 6 years of age; safety is not established for children younger than 6.

Use requires caution or is not recommended for patients with certain comorbidities. Individuals with Bronchospastic Disease (like severe asthma) should generally avoid use. Patients with Severe Hepatic Impairment require close monitoring and consideration for lower doses due to altered metabolism. Caution is also advised for patients with Diabetes Mellitus or Peripheral Vascular Disease.

Reproductive Status Limitations

During pregnancy, Metofol should only be used if the expected benefit decisively outweighs the potential risk to the fetus. The medicine is excreted into human milk, and caution is recommended during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metofol's (Metoprolol) interaction profile is defined by pharmacokinetic elevation and pharmacodynamic reinforcement, as detailed in official regulatory documents. No combinations are formally listed as contraindicated in the FDA prescribing information.

Metabolic Interactions: The drug is primarily cleared via the CYP2D6 enzyme. Co-administration with potent CYP2D6 inhibitors (including certain antidepressants like Fluoxetine, Paroxetine, and antiarrhythmics like Quinidine) is officially documented to increase Metofol plasma concentrations due to reduced metabolic clearance. This risk of increased exposure is noted to be heightened in patients with impaired hepatic function.

Pharmacodynamic Interactions: Co-administration with other medicines that affect heart function may lead to additive effects. For instance, co-use with non-dihydropyridine Calcium Channel Blockers (e.g., Verapamil, Diltiazem) or Digitalis Glycosides may result in additive negative effects on heart rate or atrioventricular conduction. Other Catecholamine-Depleting Drugs (e.g., Reserpine) can similarly produce additive bradycardia or hypotension.

Other Pharmacokinetic Interactions: Specific drugs like Cimetidine and Hydralazine are also documented to increase Metofol plasma concentration. Furthermore, Food Intake is officially documented to increase the bioavailability of Metofol, resulting in higher systemic exposure. The regulatory label does not mandate specific timing separation rules for administration.

Mechanism of Action

Metofol functions as a beta1-adrenergic receptor antagonist, demonstrating cardioselectivity by preferentially binding to beta1-receptors located primarily on cardiac tissue. This competitive interaction blocks the effects of endogenous catecholamines, such as norepinephrine and epinephrine, from binding to and activating the receptor.

At the molecular level, this blockade inhibits the catecholamine-mediated activation of the adenylyl cyclase enzyme. The resulting reduction in the intracellular synthesis of cyclic adenosine monophosphate (cAMP) subsequently dampens the activity of protein kinase A (PKA). The PKA signaling cascade normally promotes calcium influx into the myocardial cell via L-type calcium channels. By inhibiting this pathway, Metofol decreases intracellular calcium availability for myofilament interaction.

This leads to a negative inotropic effect (reduced myocardial contractility) and a negative chronotropic effect (reduced heart rate) by slowing the conduction velocity through the sinoatrial and atrioventricular nodes. A further systemic consequence is the suppression of renin release from the juxtaglomerular apparatus in the kidney, which is also regulated by beta1-receptor activation. The combined physiological consequences include a reduction in cardiac output and systemic blood pressure.

Dosage and Administration Information

The administration of Metofol (Folic Acid) is governed by instructions detailing the route, dosage, frequency, and specific handling procedures.

Administration Scope

Metofol is primarily taken via the oral route using available tablets or capsules, but it can be administered through parenteral routes (Intravenous, Intramuscular, or Subcutaneous) when a patient's gastrointestinal absorption is impaired. The standard regimen is once daily (qd) for all phases of use. The standard therapeutic dosing for deficiency correction often involves up to 1 mg daily, or up to 5 mg daily for malabsorption states, with a typical maintenance dose of 0.4 mg daily following correction. Specific parameters exist for defined populations, such as pregnant or lactating women, who may be instructed on specific maintenance doses higher than the standard adult quantity.

Procedural Structure

The use follows a defined procedural sequence: treatment begins with a short-term, therapeutic once-daily quantity, followed by a transition to a lower long-term daily maintenance regimen. A crucial procedural instruction is that if a dose is missed, individuals are instructed not to take a double dose to compensate. This structured administration is intended to standardize the drug’s delivery.

Recent Clinical Evidence

Metofol: Recent Clinical Evidence


Evidence on Joint Swelling and Stiffness

Clinical research has explored whether this substance was studied for potential anti-inflammatory effects and was evaluated in studies focusing on changes in joint swelling and stiffness related to conditions such as osteoarthritis. Research has examined its effect on patient-reported symptoms of moderate to severe arthritis.

  • A Phase II trial involving 150 participants evaluated the substance over a 12-week period. The trial reported a decrease in pain scores over that time. Swelling scores were also examined as a secondary endpoint in this study.
  • The results of one large-scale meta-analysis explored the consistency of these findings across diverse patient populations, reporting mixed findings regarding changes in joint stiffness.

Studies on Pain Relief

Clinical research has extensively examined the substance's effect on pain. The primary endpoint in most trials was the change in the Visual Analogue Scale (VAS) pain score.

  • Two major Randomized Controlled Trials (RCTs) reported that participants who received the substance had lower average pain scores than the placebo group after four weeks of evaluation.
  • Research has explored the potential role of this substance for acute flare-ups.

Use and Observed Effects

Information is available concerning side effects. Studies evaluated outcomes related to the long-term use of the substance. Common adverse events reported in clinical trials included headache and mild gastrointestinal upset.

  • Clinical trial data includes information on the substance's use in participants with pre-existing heart conditions.
  • Studies have examined whether the combination of this substance with a standard anti-rheumatic drug is associated with changes in mobility when compared to monotherapy.

Other Research Areas

Early research explored the effect of the substance on chronic back pain. These initial studies focused on safety parameters and provided preliminary data for later-stage research.

Key Studies & References

  1. Long-term Tolerability and Adverse Event Profile of [Metofol] in Patients with Chronic Inflammatory Disease
  2. Clinical Guidance for the Management of Inflammatory Arthritis (e.g., NICE Guideline NG200)

Frequently Asked Questions (FAQ)

Common questions about Metofol (FAQ)


Q: Is Metofol the same as Metoprolol?

Official documents describe Metofol as a medicinal preparation whose active ingredient is Metoprolol, a type of medicine classified as a beta-blocker. This clarification is intended to address potential confusion related to the drug's different names and formulations.

Q: Is Metofol a beta-blocker?

Yes, official documents classify the active ingredient in Metofol as a beta1-adrenergic receptor antagonist, which is commonly known as a beta-blocker. This classification relates to how the medicine acts on the body's cardiovascular system.

Q: What's the difference between immediate-release and extended-release Metofol?

Regulatory documents describe two main types: an immediate-release form, which is associated with a multiple-times-per-day schedule, and an extended-release form, which is typically taken once daily for a sustained effect. Regulatory documents indicate that the different formulations are associated with different administration schedules.

Q: Can I stop taking Metofol if I feel better?

Official warnings strictly advise against abruptly stopping this medicine. Sudden discontinuation may cause a temporary worsening of certain medical conditions, such as chest pain or heart rhythm problems. Official documents caution that any change to the regimen requires professional review.

Q: Can Metofol make you feel tired?

Tiredness, also known as fatigue, is listed in official documents as a common adverse reaction reported with the use of this medicine. Fatigue is listed as an adverse reaction, and official documents note this is commonly observed when beginning the medication.

Q: Is it normal to have dizziness when starting Metofol?

Yes, official product information lists dizziness as a common adverse reaction associated with the use of the drug. Regulatory documents indicate that dizziness is often noted during the initial phase of treatment.

Q: How long does it take for Metofol to start working?

The drug is described as having a rapid initial action on heart rate and blood pressure. However, the full expected benefit, such as stable blood pressure reduction, may take about one week to be fully observed.

Q: Can Metofol be used for migraines?

The immediate-release form of Metoprolol (Metoprolol Tartrate) is officially approved for the prevention of migraine headaches in some regulatory regions. This is in addition to its use for heart conditions like high blood pressure.

Q: Is Metofol used for anxiety or just for heart conditions?

Official indications for this drug include the treatment of high blood pressure, angina, and heart failure. Use for conditions such as anxiety is not among the formal regulatory approvals for the drug.

Q: Will Metofol change my blood pressure readings?

Yes, the drug is formally indicated for the treatment of high blood pressure. This blood pressure reduction is a recognized physiological consequence of the medicine's mechanism of action.

Q: Will Metofol affect my heart rate?

Yes, the mechanism of action of the drug includes a described negative chronotropic effect, which means it works to slow the heart rate. The reduction in heart rate is a described action of the medicine.

Q: Does Metofol cause weight gain?

Weight gain is not listed as a common specific side effect in official safety data. However, regulatory documents state that unexplained or sudden weight gain can be a symptom associated with heart failure, a condition for which this medicine is sometimes used.

Q: Does Metofol interact with alcohol?

Official information indicates that alcohol consumption is noted to increase the risk of side effects such as dizziness and fatigue. Alcohol may also lead to additive blood pressure lowering effects when taken with this medicine.

Q: Does Metofol interact with common painkillers like ibuprofen?

Yes, official drug interaction lists include Nonsteroidal Anti-inflammatory Drugs (NSAIDs) such as ibuprofen. Concurrent use may decrease the blood pressure-lowering effects of Metofol.

Q: Is Metofol safe to take with cold and flu medicine?

Cold and flu medicines often contain ingredients, such as decongestants, that can counteract the effects of Metofol. Official warnings advise caution with co-administration of sympathomimetic agents found in some cold remedies.

Q: Can you drink coffee while taking Metofol?

Caffeine, a stimulant found in coffee, may potentially work against the blood pressure-lowering effects of the medicine. Official information indicates that consumption of excessive caffeine may need to be addressed.

Q: Can Metofol be taken with supplements or vitamins?

Regulatory documents advise caution with all co-administered substances. They note that some vitamins, supplements, and herbal products can affect the drug's activity. Official documents caution that any co-administration requires professional review.

Q: Do other medicines make Metofol less effective?

Yes, official information indicates that some other medicines, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs), are documented to decrease the expected blood pressure-lowering effect of the drug.

Q: Can Metofol be taken on an empty stomach?

The medicine should be taken consistently, either with food or immediately following a meal. Official information notes that food significantly increases the body's absorption of the active ingredient.

Q: Can Metofol be crushed or split?

Extended-release tablets are generally scored and can be divided, but they must not be crushed or chewed. The extended-release function relies on the tablet remaining intact to control the release rate of the active ingredient.

Q: What are the signs of taking too much Metofol?

Official documents on overdose describe signs that include pronounced slowing of the heart rate (bradycardia), excessively low blood pressure (hypotension), and possibly severe dizziness or symptoms of heart failure.

Q: Can children or teenagers take Metofol?

Regulatory documents state that use for high blood pressure is established for children aged ge 6 years. Safety and effectiveness are not established for children younger than 6.

Q: Are there any specific warnings about Metofol for people with diabetes?

A specific warning is noted for patients with diabetes mellitus. Official information indicates that the medicine may mask certain signs of low blood sugar (hypoglycemia), particularly fast heart rate.

Q: Is Metofol safe for older adults?

While commonly used, official information indicates that a lower clearance rate may necessitate specific monitoring when used by older adults. This is due to age-related changes in organ function, such as liver and kidney impairment.

Q: Does Metofol affect kidney function?

Regulatory information indicates that the drug is extensively metabolized by the liver. Dose adjustment is typically not required for patients with impaired kidney function, although caution is advised.

Q: Is Metofol known to cause hair loss?

Hair loss (alopecia) is listed in regulatory documentation as a rare adverse event that has been reported post-marketing with this drug. It is not listed among the most common side effects.

Q: Does Metofol cause mood changes?

Yes, official documents list mood changes, including depression and sleep disturbances, as adverse reactions associated with the use of this medicine. Users should be aware of this possibility.

Q: Is Metofol considered a preventive medication?

The drug is indicated for the long-term management of chronic conditions such as high blood pressure and heart failure. Additionally, one formulation is officially approved for the prophylaxis (prevention) of migraine headaches.

Q: How is Metofol eliminated from the body?

The drug is extensively metabolized by the liver, primarily using the CYP2D6 enzyme. The inactive drug components (metabolites) are then primarily eliminated from the body through the urine.

Q: What if I take Metofol late in the day?

The extended-release formulation is intended to provide a stable, consistent effect over 24 hours. Taking the dose consistently at the same time each day is recommended to maintain stable concentrations of the drug in the body.

Q: Can women who are pregnant or breastfeeding use Metofol?

Regulatory documents state that use during pregnancy should only occur if the potential benefit justifies the potential risk to the fetus. The medicine is also excreted into human milk, and caution is recommended during lactation.

Q: Is there a maximum time someone can take Metofol?

The drug is often used for the long-term management of chronic conditions such as heart failure and high blood pressure. There is no maximum duration specified in official documents for its continuous use.

Q: Are there different strengths of Metofol tablets?

Yes, the extended-release tablets are officially supplied in different strengths. These typically include 25 mg, 50 mg, 100 mg, and 200 mg, as noted in the official prescribing information.

Q: Does Metofol require special monitoring?

Yes, the medicine requires specific monitoring, including regular checks of heart rate and blood pressure. This monitoring is especially important when the dose is started or changed, and in patients with certain pre-existing conditions.

Q: Is Metofol approved in other countries besides the US?

Metoprolol is widely used and is included on the World Health Organization’s List of Essential Medicines. This indicates its international regulatory approval and importance in healthcare systems globally.

Q: What foods should I avoid while taking Metofol?

Official information notes that food increases the absorption of the medicine, so it should be taken consistently with meals. However, no specific common food products are formally restricted or listed as prohibited in the product labeling.

Q: Are there any long-term side effects of taking Metofol?

Official safety data lists adverse reactions reported across the period of use. Long-term use is not currently known to increase the risk of these side effects compared to short-term use, though monitoring is important.

Q: What is the shelf life of Metofol?

The official shelf life is established through stability testing required by regulatory bodies. It is typically up to two years from the date of manufacture when stored under the specified conditions.

Q: Does Metofol expire and is it safe to take after the expiration date?

All officially approved medicines have an expiration date. Taking any medicine after this date is not recommended because the drug may lose its intended strength, quality, or purity.

Q: Can Metofol be taken with herbal remedies?

Official information advises caution and indicates that potential interactions with herbal remedies should be addressed. Specific studies may not cover every herbal remedy, so this caution applies broadly.

How should Metofol be stored and disposed of?

How to Store and Dispose of Metofol?

Metofol (Metoprolol Succinate) must be stored according to official regulatory specifications to maintain its stability and effectiveness.


Official Storage Requirements

  • Temperature: Store at Controlled Room Temperature, defined as 25 C (77 F). Permitted excursions are between 15 C and 30 C (59 F and 86 F).
  • Protection: The medicine must be protected from moisture and stored in a tight container.
  • Child Safety: Keep the product out of the reach of children and pets to prevent accidental ingestion.

️ Disposal Instructions

Disposal of unused or expired tablets should follow official guidelines. The preferred method is using an authorized drug take-back program. If a take-back option is unavailable, the product may be mixed with an unpalatable substance (e.g., dirt, coffee grounds) and sealed in a bag for disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metofol found in:

A-Z Index: